Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: COVID-19 Vaccines   Oct 08, 2020  3 years, 6 months, 1 week, 3 days, 14 hours, 24 minutes ago

MUST READ! Study Involving Case Of Reinfection Questions Efficacy Of COVID-19 Vaccines Under Development Or Trials Against Emerging Mutated Strains

MUST READ! Study Involving Case Of Reinfection Questions Efficacy Of COVID-19 Vaccines Under Development Or Trials Against Emerging Mutated Strains
Source: COVID-19 Vaccines   Oct 08, 2020  3 years, 6 months, 1 week, 3 days, 14 hours, 24 minutes ago
COVID-19 Vaccines: A group of American researchers from  the Swedish Medical Center-Seattle, University of Washington-Seattle, Stanford University-California, LabCorp-Seattle and the Vaccine and Infectious Disease Division, Fred Hutch-Seattle after reviewing a case of a patient who got re-infected with a different strain of the SARS-CoV-2 coronavirus ie the more potent and infectious D614G mutated strain are now questioning the effectiveness of the current vaccines that are under development or in phase 3 trials.



The case patient had anti-SARS-CoV-2 IgG antibodies in the first weeks after reinfection, but notably, levels of anti-RBD IgG were relatively low, with no evidence of blocking antibodies to the RBD-ACE2 complex. ACE2 blocking increased only slightly by day 42, likely due to IgA antibodies. In the B cell repertoire, new clones do not emerge by day 18 after reinfection, lending support to immune recognition of prior infection or suggesting a deficiency in the developing response to the reinfection. 

While the nAb titers immediately at the time of reinfection are not known, by day 14 after reinfection, nAb levels were comparable to those observed after boosted vaccination.21 By day 42 nAb response showed a 1.5-fold increase to Wuhan pseudovirus, and a 2.6- fold increase to D614G pseudovirus. 

Taken together, these findings suggest that poorly developed or waned antibodies against the D614 virus formed after primary infection in March were not protective against reinfection with the D614G spike variant acquired in July. 

These results could have important implications for the success of vaccine programs based on the Wuhan strain.

The study findings cum report are published on a preprint server and are currently being peer-reviewed. https://www.medrxiv.org/content/10.1101/2020.09.22.20192443v1

According to the study team the patient f